Advertisement

Tumor Biology

, Volume 35, Issue 8, pp 7391–7392 | Cite as

How to optimize the sequential use of novel therapeutics in metastatic prostate cancer patients? Response should be found in prostate cancer tissue

  • Edoardo Francini
  • Giandomenico Roviello
Research Commentary

Dear Editor,

To date, Food and Drug Administration (FDA) approved abiraterone acetate (AA), enzalutamide (E), and cabazitaxel (Cbz) as new options for patients with castration-resistant prostate cancer (CRPC) whose disease progresses during or after docetaxel (D) treatment. However, little data are available about optimal sequencing for these agents. Recently, Schrader et al. [1] described the effects of E after AA failure. Their data showed that E is only moderately effective and suggested that cross-resistance between AA and E was a common phenomenon. Conversely, Pezaro et al. demonstrate significant Cbz activity in CRPC progressing after treatment with D and AA or E [2]. In this study, activity on Cbz appeared more modest in the cohort not treated with AA nor E, while higher antitumour activity with Cbz in AA- and E-treated patients was reported. Authors hypothesized that the constitutively activated androgen receptor (AR) splice variants, which generally could result in resistance...

Keywords

Prostate Cancer Androgen Receptor Abiraterone Enzalutamide Cabazitaxel 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Conflicts of interest

None

References

  1. 1.
    Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol. 2013;65:30–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Pezaro CJ, Omlin AG, Altavilla A, Lorente D, Ferraldeschi R, Bianchini D, et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur Urol. 2013. doi: 10.1016/j.eururo.2013.11.044.Google Scholar
  3. 3.
    Sun Y, Niu J, Huang J. Neuroendocrine differentiation in prostate cancer. Am J Transl Res. 2009;1:148–62.PubMedCentralPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Medical Oncology Unit, Policlinico Umberto I HospitalUniversity of RomeRomeItaly
  2. 2.Medical Oncology UnitUniversity of SienaSienaItaly

Personalised recommendations